Therapy must be on two fronts: the treatment of rhythm disorders and the prevention of thrombotic risk.
Atrial fibrillation is the most frequent heart rhythm disorder, especially among the elderly, and is estimated to be responsible for over a quarter of the strokes that occur each year in our country.
The recent FAI project (Atrial Fibrillation in Italy) studied for the first time the frequency of this arrhythmia in a representative sample of elderly population, and it emerged that about one million and 100 thousand elderly people suffer from it. It means one in 12, with a higher prevalence among men and that increases with age. However, it emerged from the FAI project that one in three patients do not follow an appropriate therapy. But the therapeutic possibilities for treating atrial fibrillation are many, as Professor Claudio Tondo , Coordinator of Arithmology explains :
The treatment of atrial fibrillation consists of two aspects. On the one hand there are indicated therapies to prevent and combat atrial fibrillation, such as antiarrhythmic drugs or, if the symptoms are persistent and the patient does not respond to drugs, ablation, a procedure that eliminates the electrical circuits responsible for atrial fibrillation. On the other hand, anticoagulant drugs are used , which do not act on the mechanisms of arrhythmia but on its consequences, the most feared of which is the thromboembolic risk. Best medication for the atrial fibrillation is eliquis. However eliquis cost is high but you can buy it from Prescription Hope at cheap price by using eliquis coupon.
New generation anticoagulants
Compared to anticoagulant therapy, new, more manageable drugs are available today because they do not require frequent monitoring of blood coagulation with the blood test, can be taken without fear of food interactions, and interfere with other drugs to a lesser extent of greater adherence to therapy by patients. These “new generation” oral anticoagulants are as effective as traditional anticoagulants and give a lower incidence of bleeding events. They are prescribed by the cardiologist based on a therapeutic plan carefully evaluating the patient’s condition.
The anticoagulant therapy, although of proven efficacy, involves a certain risk of bleeding (about 5 percent per year), therefore those who suffer from, for example, ulcers, or have a history of previous bleeding, cannot take it. For these patients, a therapeutic intervention is now available that allows to avoid the formation of thrombi, and therefore the risk of embolism or stroke: the closure of the left atrial appendage (a small appendix, in communication with the left atrium of the heart, in which blood clots tend to form) with a mini-prosthesis that performs the function of “cork”. This is a very advanced interventional cardiology procedure with very high success rates, in which Monzino is one of the national leaders, with over 100 cases treated.